Mesenchymal Stem/Stromal Cells: CLINICAL-GRADE HUMAN SYNOVIAL FLUID-DERIVED MESENCHYMAL STEM CELLS FOR DEGENERATIVE MENISCUS THERAPY

Uysal O., Avci H., Bagis S., Sevimli T. S., Ozel C., Cevizlidere B. D., ...Daha Fazla

CYTOTHERAPY, cilt.25, sa.6, ss.92, 2023 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 25 Sayı: 6
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/s1465-3249(23)00296-7
  • Dergi Adı: CYTOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.92
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

When meniscal tissue is damaged, there is no gold standard medication and/or surgical treatment that can regenerate the damaged tissue. Currently, although the most effective treatment approach is the surgical method-partial meniscectomy, it provides only symptomatic improvement. The aim of this study is to develop the stem cell treatment protocol in addition/alternative to the surgical method adapt it to the clinical practices, suitable for use in human treatment. For this purpose, all steps of the production process as a Good Manufacturing Practices (GMP)-grade cellular therapy product from the collection of the synovial fluid sample from the patient until the release of the final product; the standard operation procedure of the production was prepared according to the legal regulations.